2019
EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas
Maracaja DLV, Puthenpura V, Pels SG, O’Malley D, Sklar JL, Finberg KE, Xu ML. EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas. Applied Immunohistochemistry & Molecular Morphology 2019, 28: 725-730. PMID: 31789821, DOI: 10.1097/pai.0000000000000820.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorDiagnosis, DifferentialEpstein-Barr Virus InfectionsHerpesvirus 4, HumanHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryImmunophenotypingKaryopherinsLymphoma, Large B-Cell, DiffuseMaleMediastinal NeoplasmsMutationReceptors, Cytoplasmic and NuclearThymus NeoplasmsYoung AdultConceptsPrimary mediastinal large B-cell lymphomaEpstein-Barr virusLarge B-cell lymphomaB-cell lymphomaEBV positivityMediastinal lymphomaMediastinal large B-cell lymphomaMediastinal gray zone lymphomaGray zone lymphomaRole of immunohistochemistryClassical Hodgkin lymphomaEBV expressionMediastinal massTherapeutic optionsHodgkin's lymphomaClassic immunophenotypeLymphomaXPO1 mutationsMutational profilingPositivityNext-generation sequencingImmunophenotypeSomatic mutationsK mutationTumorsA Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R‐CHP Chemotherapy
Mallipudi RM, Alquran L, Shenoy VA, Leslie LA, Conti JA. A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R‐CHP Chemotherapy. Case Reports In Oncological Medicine 2019, 2019: 4121234. PMID: 31110830, PMCID: PMC6487142, DOI: 10.1155/2019/4121234.Peer-Reviewed Case Reports and Technical NotesGray zone lymphomaDiffuse large B-cell lymphomaClassical Hodgkin lymphomaNon-Hodgkin lymphomaB-cell lymphomaComplete responseAnti-CD30 antibody drugLarge B-cell lymphomaViable therapeutic candidateCurrent treatment optionsT-cell lymphomaStage IIIABrentuximab vedotinRefractory HodgkinRepeat biopsyChallenging diagnosisHodgkin's lymphomaTreatment optionsImmunohistochemical studyRare casePET scanningLymphomaTherapeutic candidateStandardized guidelinesAntibody drugs
2018
Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma
Pelland K, Mathews S, Kamath A, Cohen P, Hudnall SD, Cotta CV, Xu ML. Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma. Applied Immunohistochemistry & Molecular Morphology 2018, 26: e101-e106. PMID: 29189264, DOI: 10.1097/pai.0000000000000615.Peer-Reviewed Original ResearchConceptsPrimary mediastinal large B-cell lymphomaMediastinal gray zone lymphomaClassic Hodgkin lymphomaGray zone lymphomaPD-L1Mediastinal large B-cell lymphomaLarge B-cell lymphomaDendritic cell markersB-cell lymphomaCell gene expression profilesHodgkin's lymphomaRare entityCD123LymphomaTherapeutic potentialCell markersTherapeutic significanceGenetic featuresGene expression profilesFascinRepresentative sectionsExpression profilesImmunohistochemistryTumorsDiagnosis
2017
Pathology of Hodgkin Lymphoma
Hudnall S. Pathology of Hodgkin Lymphoma. Molecular Pathology Library 2017, 13-34. DOI: 10.1007/978-3-319-68094-1_2.Peer-Reviewed Original ResearchReed-Sternberg cellsNodular lymphocyte predominant Hodgkin lymphomaLymphocyte predominant Hodgkin lymphomaPredominant Hodgkin lymphomaHodgkin's lymphomaClassical Reed-Sternberg cellsB cellsLP cellsMediastinal gray zone lymphomaCD4 T cellsMantle zone B cellsGray zone lymphomaReactive inflammatory infiltrateGerminal center B lymphocytesB-cell originClassical Hodgkin lymphomaB-cell immunophenotypeClonal cellsMedium-sized mononuclear cellsInflammatory infiltrateClinical featuresCastleman's diseaseHistopathologic featuresImmunophenotypic featuresReactive infiltrate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply